Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in t (Q56974816)
Jump to navigation
Jump to search
scientific article published on 30 December 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in t |
scientific article published on 30 December 2013 |
Statements
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement (English)
Caterina De Benedittis
1 reference
Stefania Paolini
Claudia Venturi
Paola Bresciani
Marzia Salvucci
Domenico Russo
Simona Sica
Ester Orlandi
Tamara Intermesoli
Antonella Gozzini
Massimiliano Bonifacio
Fabrizio Pane
Ilaria Iacobucci
Michele Baccarani
Giovanni Martinelli
30 December 2013
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference